leadf
logo-loader
viewSpire Healthcare Group

Spire Healthcare finally a ‘buy’ for Liberum over long-term prospects

Analysts said the massively increased waiting lists are likely to provide better long-term revenue visibility than ever

Spire Healthcare Group - Spire Healthcare finally a ‘buy’ for Liberum over long-term prospects

Spire Healthcare Group PLC (LON:SPI) was upgraded to a ‘buy’ after three years of ‘hold’ by Liberum over good potential for long-term prospects.

The broker said that while the pandemic has been a major disruption for the hospital group, the massively increased waiting lists are likely to provide better long-term revenue visibility than ever.

“New management has significantly improved the operational quality of the business and its now well-placed to meet this demand once elective procedures begin - we assume fourth quarter,” analysts commented.

“COVID-19 removes at least six months of operations for Spire but we only expect a 15% increase in net debt and the longer-term outlook is actually better than before.”

Shares, which are trading at a third of February’s values, were flat at 75.5p on Tuesday morning.

Quick facts: Spire Healthcare Group

Price: 96.3 GBX

LSE:SPI
Market: LSE
Market Cap: £386.24 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

IXICO plays 'pivotal role' after announcing £2m extension to Huntington's...

IXICO PLC's (LON:IXI) Lammert Albers talks to Proactive London about the £2m extension to a contract to provide additional imaging services for a pivotal Huntington's disease (HD) study. Albers describes this as a 'strong suit' having started very early and now carrying out a Phase III...

9 hours, 42 minutes ago

2 min read